5 Key Takeaways
-
1
The phase I trial evaluated CAR T cells targeting CD19, CD20, and CD22 in patients with relapsed or refractory B-cell malignancies.
-
2
Point-of-care manufacturing produced CAR T cells in a median of 7 days, with successful production for 16 of 17 patients.
-
3
Among 16 treated patients, the overall response rate was 50%, and 38% achieved complete responses.
-
4
Five of 6 patients with B-cell non-Hodgkin lymphoma achieved complete remission, and 4 remained in remission beyond 1 year.
-
5
No severe cytokine release syndrome, dose-limiting toxicities, or immune effector cell-associated neurotoxicity syndrome occurred; pretreatment T-cell exhaustion markers were higher in patients whose
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
